CancerNetwork via MedWorm.com

MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'CancerNetwork' source.

Latest articles

Patients See Benefit with Telemedicine Visits Compared with In-Person Visits

It was suggested that telemedicine for patients in an interventional radiology group increases access to care and allows for more efficient use of physician time and resources. (Source: CancerNetwork)

Study May Aid AYAs in Weighing Risks, Benefits of Clinical Trial Participation

Trends in favor of better clinical outcomes were observed for those on-trial in this retrospective matched cohort study of patients with cancer who were treated on a phase III clinical trial compared with those who received standard therapy and/or were off trial. (Source: CancerNetwork)

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC

Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)

Study Supports Increased Referrals of Genetic Testing in African American Women

A recent study demonstrated the validity of current breast cancer testing panels for use in African American women and provides a basis for increased referral of this patient population for cancer genetic testing. (Source: CancerNetwork)

Clinical Improvement Found After Administration of Acalabrutinib for Patients with COVID-19

A recent study, sparking further trials for investigation, saw improved clinical outcomes and reduced markers of inflammation for patients with severe COVID-19 after treatment with acalabrutinib, a selective BTK inhibitor. (Source: CancerNetwork)

Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma

Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies. (Source: CancerNetwork)

Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma

The combination use of belantamab mafodotin plus bortezomib   and dexamethasone induced high clinical benefit rates and a tolerable safety profile in patients with relapsed or refractory multiple myeloma. (Source: CancerNetwork)

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial

The trial compared zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenstr öm macroglobulinemia. (Source: CancerNetwork)

JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma

The CAR T-cell therapy continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma. (Source: CancerNetwork)

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings

The study evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Source: CancerNetwork)

Discover, share and read the best on the web

Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters! Get unfiltered news feeds or filter them to your liking.

Get Inoreader
Inoreader - Subscribe to RSS Feeds, Blogs, Podcasts, Twitter searches, Facebook pages, even Email Newsletters!